Areas of Focus
- Tumor Pharmacology
Work Experience
- 2016-11 to Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Master's Supervisor
- 2016-04 to Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Associate Researcher
- 2014-09 to 2016-04 - Yale University - Visiting Scholar
- 2012-09 to 2014-09 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Associate Researcher
- 2011-12 to 2012-08 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Assistant Researcher
- 2009-07 to 2011-11 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Postdoctoral Researcher
- 2004-09 to 2018-06 - Shanghai Jiao Tong University - PhD in Biochemistry and Molecular Biology
- 1999-09 to 2004-07 - Wenzhou Medical University - Bachelor's in Clinical Medicine
Academic Background & Achievements
- 2014-09 to 2016-04 Visiting Scholar: Yale University
- 2004-09 to 2018-06 PhD in Biochemistry and Molecular Biology: Shanghai Jiao Tong University
- 1999-09 to 2004-07 Bachelor's in Clinical Medicine: Wenzhou Medical University
Publications
- Integrated multi-omics analysis reveals gut microbiota dysbiosis and systemic disturbance in major depressive disorder, First Author, 2024
- Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth, Not mentioned, 2023
- Fine-tuning Bacterial Cyclic di-AMP Production for Durable Antitumor Effects Through the Activation of the STING Pathway, Not mentioned, 2023
- Structure-Activity relationship study of benzothiophene oxobutanoic acid analogues leading to novel stimulator of interferon gene (STING) agonists, Not mentioned, 2022
- Development of a novel lactate dehydrogenase A inhibitor with potent antitumor activity and immune activation, Not mentioned, 2022
- Structural insights into a shared mechanism of human STING activation by a potent agonist and an autoimmune disease-associated mutation, First Author, 2022
- Discovery of Novel Imidazo[4,5-c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis, Not mentioned, 2022
- Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration, Not mentioned, 2022
- HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities, Not mentioned, 2022
- Novel Sphingosine Kinase 1 Inhibitor Suppresses Growth of Solid Tumor and Inhibits the Lung Metastasis of Triple-Negative Breast Cancer, Not mentioned, 2022
- Genomic Heterogeneity and the Small Renal Mass, Second Author, 2018
- Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration, Eleventh Author, 2017
- Development of the First Generation of Disulfide-Based Subtype Selective and Potent Covalent Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors, Second Author, 2017
- Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity, Not mentioned, 2017
- Phosphoglycerate mutase 1 (PGAM1) regulates dNTP pool and promotes homologous recombination repair in cancer cells., Not mentioned, 2017
- Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma., Fifth Author, 2016
- MET Inhibition in Clear Cell Renal Cell Carcinoma, First Author, 2016
- Lactate Dehydrogenase B Is Associated with the Response to Neoadjuvant Chemotherapy in Oral Squamous Cell Carcinoma, Eleventh Author, 2015
- JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification, Second Author, 2015
